Explore the Agenda
7:45 am Check-in & Morning Coffee
8:45 am Chair’s Opening Remarks
Unlocking New Therapeutic Potential in 2026
9:00 am Advancing IBD Therapy by Sharing New Clinical Insights & Future Directions of Recent Approvals
- Discover the latest clinical data and real-world insights to understand impacts on patient outcomes in Ulcerative Colitis and Crohn’s disease
- Learn how recent regulatory approvals are expanding treatment options and improving access for patients with IBD
- Explore future directions in IBD care by examining ongoing research, pipeline developments, and strategies for integrating new therapies into clinical practice
9:30 am Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease
- Highlighting how locally bioactivated pharmacology and translational biomarker science are converging to redefine the treatment of fibrostenotic IBD
10:00 am Transforming IBD Treatment Landscape with Anti-TL1A Based Next Generation Monospecific and Multi-specific Antibodies
- Mechanistic advantages of long-acting anti-TL1A antibodies, including optimized stability, half-life, route of administration and tissue targeting to potentially enhance efficacy and durability
- Early-stage bispecific TL1A antibodies in preclinical development, designed to address multiple disease pathways simultaneously
- Translational strategies for integrating precision medicine approaches in IBD, laying the groundwork for future patient-stratified therapy
10:30 am Speed Networking
11:00 am Morning Break & Coffee
Uncovering Emerging Biomarker Targets to Enable the Precision IBD Treatments of Tomorrow
11:30 am Precision Targeting of IL-6 Trans-Signaling: Restoring Balance Between Inflammation & Regeneration
- Present quantitative modeling insights predicting that selective trans-signaling inhibition will permit faster tissue healing than global IL-6 blockade
- Discuss translational strategies to validate these findings through biomarkers, imaging modalities, and early proof-of-concept trials
- Highlight implications for trial design, including precision endpoints, patient stratification, and integrating modeling into clinical decision making
12:00 pm Advancing Precision IBD Care Through Biomarker-Driven Insights and Translational Innovation
- Identify and validate biomarkers that stratify patient subgroups and predict therapeutic response across diverse clinical studies
- Integrate translational biomarker data from clinical and real-world models to inform disease progression and treatment outcomes
- Accelerate precision therapy development by linking biomarker discovery to targeted intervention strategies in ulcerative colitis and Crohn’s disease
12:30 pm Translating Biomarkers into Clinical Strategy: Lessons from Other Immunological Diseases for IBD
- Discuss Precision Medicine opportunities for in IBD using predictive and prognostic biomarkers, drawing parallels with immunology and Oncology programs advancing into later trials
- Unpack the gap between translational biomarker insights and real-world diagnostics, including regulatory, commercial, and scalability hurdlesDiscuss challenges in moving from translation level biomarker insights to clinically validated tools
1:00 pm Lunch Break & Networking
From Biomarkers to Bedside: Accelerating Innovation of Precision Diagnostics
2:00 pm Characterizing Pathogenic Cell Populations in Non-Responder IBD Tissues to Inform Targeted Therapeutic Development
- Characterize pathogenic cell types and molecular factors enriched in non-responder IBD tissues to uncover mechanisms driving treatment resistance
- Leverage tissue-level cellular insights to identify potential therapeutic targets aimed at restoring response or achieving durable remission
- Discuss methodological approaches for profiling non-responder tissues and building a framework linking tissue and blood biomarkers to predict clinical outcomes
2:30 pm Using Blood-Based Epigenetic Signatures to Personalize First-Line Biologic Therapy in Crohn’s Disease
- Investigating a scalable, blood-derived DNA methylation panel designed to guide first-line biologic selection at diagnosis, aiming to move beyond today’s trial-and-error paradigm and reduce early complications linked to ineffective therapy
- Leveraging a validated epigenetic algorithm undergoing testing in the OMICRON clinical trial to improve therapeutic success rates
- Establishing a blueprint for cross-disease precision medicine, with methylation markers and machine-learning pipelines engineered for translation
3:00 pm Scientific Poster Session
4:00 pm Afternoon Break & Networking
Transforming Translational Research with Human-Relevant Models to Enhance Prediction of Clinical Outcomes
4:15 pm Looking Beyond the Mouse to Accelerate Preclinical & Translational Activities
- Identify the limits of traditional murine models and where they fail to predict human trial outcomes
- Using advanced human-based models to capture the complexity and variability of patient responses, enabling more accurate therapeutic development
- Empower researchers with promising tools such as organoids, organ on chip, and patient-derived cells for human-relevant biology that streamline candidate selection, and support precision medicine approaches
4:45 pm Reprogramming Protein Therapeutics to Restore Immune Balance in Animal Models
- Advancing a novel protein platform toward safer, precision treatments for inflammatory disease
- Leveraging embedded epitope random copolymer proteins to reprogram immunity without suppressing healthy responses
- Demonstrating disease-specific efficacy in multiple animal models of Crohn’s disease, uveitis, and multiple sclerosis